About camp4 therapeutics corp - CAMP
CAMP4 Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a class of RNA-targeting therapeutics for upregulating gene expression and restoration of healthy protein levels to treat a broad range of genetic diseases. Its lead product candidate is CMP-002. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
CAMP At a Glance
CAMP4 Therapeutics Corp.
One Kendall Square
Cambridge, Massachusetts 02139
| Phone | 1-617-651-8867 | Revenue | 3.50M | |
| Industry | Biotechnology | Net Income | -80,403,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 436.503% | |
| Fiscal Year-end | 12 / 2026 | Employees | 48 | |
| View SEC Filings |
CAMP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 53.24 |
| Price to Book Ratio | 6.67 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.534 |
| Enterprise Value to Sales | 22.111 |
| Total Debt to Enterprise Value | 0.026 |
CAMP Efficiency
| Revenue/Employee | 72,875.00 |
| Income Per Employee | -1,675,062.50 |
| Receivables Turnover | 22.568 |
| Total Asset Turnover | 0.036 |
CAMP Liquidity
| Current Ratio | 7.354 |
| Quick Ratio | 7.354 |
| Cash Ratio | 7.146 |
CAMP Profitability
| Gross Margin | 53.145 |
| Operating Margin | -1,488.308 |
| Pretax Margin | -2,298.542 |
| Net Margin | -2,298.542 |
| Return on Assets | -81.996 |
| Return on Equity | -145.069 |
| Return on Total Capital | -161.848 |
| Return on Invested Capital | -136.162 |
CAMP Capital Structure
| Total Debt to Total Equity | 4.138 |
| Total Debt to Total Capital | 3.974 |
| Total Debt to Total Assets | 1.676 |
| Long-Term Debt to Equity | 3.538 |
| Long-Term Debt to Total Capital | 3.398 |